Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?

Thillai K, Lam H, Sarker D, Wells CM.

Oncotarget. 2017 Feb 21;8(8):14173-14191. doi: 10.18632/oncotarget.13309. Review.

2.

PAK2 promotes migration and proliferation of salivary gland adenoid cystic carcinoma.

Deng WW, Wu L, Bu LL, Liu JF, Li YC, Ma SR, Yu GT, Mao L, Zhang WF, Sun ZJ.

Am J Transl Res. 2016 Aug 15;8(8):3387-97. eCollection 2016.

3.

GL-1196 Suppresses the Proliferation and Invasion of Gastric Cancer Cells via Targeting PAK4 and Inhibiting PAK4-Mediated Signaling Pathways.

Zhang J, Zhang HY, Wang J, You LH, Zhou RZ, Zhao DM, Cheng MS, Li F.

Int J Mol Sci. 2016 Apr 11;17(4):470. doi: 10.3390/ijms17040470.

4.

p21-activated kinase 1 (PAK1) expression correlates with prognosis in solid tumors: A systematic review and meta-analysis.

Fang F, Pan J, Li YP, Li G, Xu LX, Su GH, Li ZH, Feng X, Wang J.

Oncotarget. 2016 May 10;7(19):27422-9. doi: 10.18632/oncotarget.8320.

5.

MiR-98 inhibits cell proliferation and invasion of non-small cell carcinoma lung cancer by targeting PAK1.

Yang G, Zhang X, Shi J.

Int J Clin Exp Med. 2015 Nov 15;8(11):20135-45. eCollection 2015.

6.

Overexpression of PAK-1 is an independent predictor of disease recurrence in colorectal carcinoma.

Al-Maghrabi J, Emam E, Gomaa W, Al-Qaydy D, Al-Maghrabi B, Buhmeida A, Abuzenadah A, Al-Qahtani M, Al-Ahwal M.

Int J Clin Exp Pathol. 2015 Dec 1;8(12):15895-902. eCollection 2015.

7.

p21-Activated Kinases 1, 2 and 4 in Endometrial Cancers: Effects on Clinical Outcomes and Cell Proliferation.

Siu MK, Kong DS, Ngai SY, Chan HY, Jiang L, Wong ES, Liu SS, Chan KK, Ngan HY, Cheung AN.

PLoS One. 2015 Jul 28;10(7):e0133467. doi: 10.1371/journal.pone.0133467. eCollection 2015.

8.

PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.

Pandolfi A, Stanley RF, Yu Y, Bartholdy B, Pendurti G, Gritsman K, Boultwood J, Chernoff J, Verma A, Steidl U.

Blood. 2015 Aug 27;126(9):1118-27. doi: 10.1182/blood-2014-12-618801. Epub 2015 Jul 13.

9.

Pak2 regulates hematopoietic progenitor cell proliferation, survival, and differentiation.

Zeng Y, Broxmeyer HE, Staser K, Chitteti BR, Park SJ, Hahn S, Cooper S, Sun Z, Jiang L, Yang X, Yuan J, Kosoff R, Sandusky G, Srour EF, Chernoff J, Clapp DW.

Stem Cells. 2015 May;33(5):1630-41. doi: 10.1002/stem.1951.

10.

Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance.

Zhao F, Siu MK, Jiang L, Tam KF, Ngan HY, Le XF, Wong OG, Wong ES, Gomes AR, Bella L, Khongkow P, Lam EW, Cheung AN.

PLoS One. 2014 Nov 20;9(11):e113478. doi: 10.1371/journal.pone.0113478. eCollection 2014.

11.

Reduced expression of p21-activated protein kinase 1 correlates with poor histological differentiation in pancreatic cancer.

Han J, Wang F, Yuan SQ, Guo Y, Zeng ZL, Li LR, Yang J, Wang DS, Liu MY, Zhao H, Liu KY, Liao JW, Zou QF, Xu RH.

BMC Cancer. 2014 Sep 3;14:650. doi: 10.1186/1471-2407-14-650.

12.

The role of p21-activated kinases in hepatocellular carcinoma metastasis.

Tse EY, Ching YP.

J Mol Signal. 2014 Aug 1;9:7. doi: 10.1186/1750-2187-9-7. eCollection 2014. Review.

13.

Motility of select ovarian cancer cell lines: effect of extra-cellular matrix proteins and the involvement of PAK2.

Flate E, Stalvey JR.

Int J Oncol. 2014 Oct;45(4):1401-11. doi: 10.3892/ijo.2014.2553. Epub 2014 Jul 22.

14.

Group I PAK inhibitor IPA-3 induces cell death and affects cell adhesivity to fibronectin in human hematopoietic cells.

Kuželová K, Grebeňová D, Holoubek A, Röselová P, Obr A.

PLoS One. 2014 Mar 24;9(3):e92560. doi: 10.1371/journal.pone.0092560. eCollection 2014.

15.

Activation of P21-activated protein kinase 2 is an independent prognostic predictor for patients with gastric cancer.

Gao C, Ma T, Pang L, Xie R.

Diagn Pathol. 2014 Mar 12;9:55. doi: 10.1186/1746-1596-9-55.

16.

The Role of Ect2 Nuclear RhoGEF Activity in Ovarian Cancer Cell Transformation.

Huff LP, Decristo MJ, Trembath D, Kuan PF, Yim M, Liu J, Cook DR, Miller CR, Der CJ, Cox AD.

Genes Cancer. 2013 Nov;4(11-12):460-75. doi: 10.1177/1947601913514851.

17.

PP1α, PP1β and Wip-1 regulate H4S47 phosphorylation and deposition of histone H3 variant H3.3.

Zhang H, Wang Z, Zhang Z.

Nucleic Acids Res. 2013 Sep;41(17):8085-93. doi: 10.1093/nar/gkt583. Epub 2013 Jul 4.

18.

Differential mRNA expression levels of human histone-modifying enzymes in normal karyotype B cell pediatric acute lymphoblastic leukemia.

Tao YF, Pang L, Du XJ, Sun LC, Hu SY, Lu J, Cao L, Zhao WL, Feng X, Wang J, Wu D, Wang N, Ni J, Pan J.

Int J Mol Sci. 2013 Feb 6;14(2):3376-94. doi: 10.3390/ijms14023376.

19.

PAK1 mediates resistance to PI3K inhibition in lymphomas.

Walsh K, McKinney MS, Love C, Liu Q, Fan A, Patel A, Smith J, Beaven A, Jima DD, Dave SS.

Clin Cancer Res. 2013 Mar 1;19(5):1106-15. doi: 10.1158/1078-0432.CCR-12-1060. Epub 2013 Jan 8.

20.

Paradoxical impact of two folate receptors, FRα and RFC, in ovarian cancer: effect on cell proliferation, invasion and clinical outcome.

Siu MK, Kong DS, Chan HY, Wong ES, Ip PP, Jiang L, Ngan HY, Le XF, Cheung AN.

PLoS One. 2012;7(11):e47201. doi: 10.1371/journal.pone.0047201. Epub 2012 Nov 7.

Supplemental Content

Support Center